Ankylosing Spondylitis News and Research

RSS

Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.

Are our bowel habits written in our DNA?

In this interview, News-Medical talks to Dr. Mauro D’Amato about how there could be clues about the regularity of bowel movements within our genes.

24 Dec 2021

Innovative artificial neural network can accurately detect radiographic sacroiliitis

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, found that an innovative new artificial neural network can detect radiographic sacroiliitis in patients with suspected axial spondyloarthritis, a progressive disease that is more common in young adults.

2 Nov 2021

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

Researchers in the UK have conducted a large population-based study showing that people with immune-mediated inflammatory diseases (IMIDs) appear to be at an increased risk of serious outcomes from coronavirus disease 2019 (COVID-19).

14 Sep 2021

Study examines the role of programmed cell death ligands in skin immune responses

T cells are a crucial part of the human adaptive immune system. In response to a foreign invader in the body, various subsets of T cells are responsible for several functions that include killing infected cells and secreting signaling molecules called cytokines that tell other immune cells where to go and what to do.

29 Jul 2021

Passive smoking and air pollution associated with arthritis risk, poor response to RA treatment

RA is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It can also cause fatigue, and the underlying inflammation may affect other body systems.

18 Jun 2021

Study explores COVID-19 outcomes in people with RA

Arani Vivekanantham and colleagues investigated the association between RA and the risk of COVID-19 diagnosis, hospitalization with COVID-19,and COVID-19-related death.

18 Jun 2021

Study discovers harmful inflammatory protein in patients with symptomatic tuberculosis

A pioneering study by UCL scientists has discovered the presence of a harmful inflammatory protein in patients with symptomatic tuberculosis (TB).

10 May 2021

Defective epithelial barrier responsible for up to two billion chronic diseases

Humans are exposed to a variety of toxins and chemicals every day. According to the epithelial barrier hypothesis, exposure to many of these substances damages the epithelium, the thin layer of cells that covers the surface of our skin, lungs and intestine. Defective epithelial barriers have been linked to a rise in almost two billion allergic, autoimmune, neurodegenerative and psychiatric diseases.

6 May 2021

Targeted Therapies Alliance provides new information, resources about the rheumatoid arthritis journey

Taking the first step and getting medical help for joint pain can be hard, but for autoimmune conditions like rheumatoid arthritis, delaying treatment can lead to increased permanent joint damage and disability.

18 Dec 2020

People of color with rheumatic disease have worse COVID-19 outcomes

New research at ACR Convergence, the American College of Rheumatology's annual meeting, reveals that people of color with rheumatic disease have worse health outcomes from COVID-19 infection, are more likely to be hospitalized to treat their coronavirus infection, and are more likely to require invasive ventilator treatment

6 Nov 2020

AI enables accurate detection of radiographic sacroiliitis in people with axial spondyloarthritis

New research presented at ACR Convergence, the American College of Rheumatology's annual meeting, shows that an artificial intelligence-based analysis model, called an artificial neural network, enables accurate detection of definite radiographic sacroiliitis in people with axial spondyloarthritis, an advance that could be useful for both diagnosis in the clinic and classification of patients for inclusion in clinical trials.

6 Nov 2020

Study: Female patients with ankylosing spondylitis can still have children

Ankylosing spondylitis (AS) is a complex chronic inflammatory disease of the spine with involvement of the sacroiliac joints.

27 Jul 2020

Trial results show efficacy of netakimab for treating moderate-to-severe plaque psoriasis

Netakimab is a humanized anti-interleukin 17A antibody approved for the treatment of moderate-to-severe plaque psoriasis.

5 Jun 2020

Pathios appoints Stuart Hughes as CEO and announces US$8.8M Series A financing round

Pathios Therapeutics Limited, an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare investors Canaan and Australia’s Medical Research Commercialization Fund managed by Brandon Capital.

9 Jan 2020

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

A new study found that very few serious infections were seen in children born to mothers with chronic inflammatory diseases who used non-TNFi biologics or tofacitinib during pregnancy compared to children not exposed to these drugs and children exposed to TNFi biologics in utero.

10 Nov 2019

Updated recommendations for treatment of patients with axial spondyloarthritis released

Today, the American College of Rheumatology, in partnership with the Spondylitis Association of America and the Spondyloarthritis Research and Treatment Network, released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

22 Aug 2019

IMAS survey reveals 74% of people living with axial spondyloarthritis struggle to find a job

The European results of the International Map of Axial Spondyloarthritis reveal that people living with axial spondyloarthritis (axSpA) – a long-term inflammatory spine condition which is as prevalent as rheumatoid arthritis – face uncertainty and worry for their future, with 74% reporting difficulties finding a job due to the condition.

From Novartis 13 Jun 2019

FDA approves treatment for adults with non-radiographic axial spondyloarthritis

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

28 Mar 2019

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.

23 Oct 2018

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.

22 Oct 2018